SS-31 (Elamipretide)
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
A mitochondria-targeted peptide marketed to reverse age-related decline in cellular energy, heart, muscle, eye, and kidney function. It stabilizes cardiolipin, and human evidence gives medium confidence to improved ATP production, while cardiac, muscle, retinal, and kidney benefits rest on thin, low-confidence trials. Injection reactions are common and pregnancy safety unknown. On September 19, 2025, the FDA granted Forzinity (elamipretide) accelerated approval only for muscle strength in Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. Aging and wellness uses are unapproved, and products sold online outside the approved drug are unregulated.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
SS-31, now sold under the brand name Forzinity (elamipretide), is a synthetic four-amino-acid peptide that targets and repairs dysfunctional mitochondria — the energy-producing structures inside every cell. Discovered by Dr. Hazel Szeto at Weill Cornell Medical College, it was the first drug specifically designed to reach the inner mitochondrial membrane and stabilize cardiolipin, a critical fat molecule that organizes the cell's energy-production machinery. SS-31 was granted FDA accelerated approval in September 2025 for Barth syndrome (a rare genetic disorder of mitochondrial function) and continues in clinical trials for age-related macular degeneration and mitochondrial myopathy.
How it works in the body
Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, a lipid essential for electron transport chain function. By stabilizing cardiolipin, it restores efficient ATP production, reduces electron leak (which generates damaging free radicals), and prevents mitochondrial collapse during cellular stress.
Research overview
SS-31 works by penetrating cells and selectively binding cardiolipin on the inner mitochondrial membrane. Cardiolipin acts like scaffolding that holds the cell's energy generators (electron transport chain complexes) in their proper arrangement. When cardiolipin is damaged — as it increasingly is with aging — energy production drops and harmful free radicals spike. SS-31 stabilizes this scaffolding, restores efficient energy (ATP) production, and reduces free radical leakage. Importantly, it only helps dysfunctional mitochondria and has no effect on healthy ones. Preclinically, a single treatment restored mitochondrial energy output to young levels in aged mouse muscle within one hour, and 8 weeks of treatment reversed age-related heart dysfunction in old mice. In human trials, a single dose improved mitochondrial ATP production in older adults' muscles (39-person randomized trial, 2021). However, larger clinical trials have had mixed results: the Barth syndrome trial led to FDA approval, but the Phase 3 mitochondrial myopathy trial (218 patients) and Phase 2 heart failure trial (71 patients) did not meet their primary endpoints. The gap between dramatic animal results and more modest human outcomes reflects the challenge of translating mitochondrial therapies to complex human diseases.
Who researches SS-31 (Elamipretide)?
Commonly researched by
People exploring muscle growth and performance
Researched for potential effects on lean mass, strength, or athletic performance.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching kidney and renal health
Studied for renal protective or nephroprotective effects.
Important considerations for
Those with Severe renal impairment
ModerateElimination pathways not fully characterized in severe organ dysfunction. Use caution.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data. Effects of mitochondrial-targeted compounds on fetal development unknown.
Safety & interactions
Do not use if
Severe renal impairment
ModerateRenal-impairment pharmacokinetics have been characterized. Severe renal impairment increases exposure; dialysis has not been studied.
General cautions
Pregnancy
AbsolutePregnancy — human safety data are unavailable; animal reproductive studies found no adverse developmental outcomes at tested exposures. Pregnancy is not an absolute contraindication. The labeled contraindication is serious hypersensitivity to elamipretide or FORZINITY excipients.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
Injection site reactions
HighFORZINITY FDA label section 6 (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75); PMID 39605874
Hypersensitivity reactions
ModerateFORZINITY FDA label, Warnings and Precautions / Adverse Reactions (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Headache, dizziness, nausea, abdominal pain, and fatigue
LowPMID 37268435 (MMPOWER-3); PMID 39605874 (ReCLAIM-2); FORZINITY FDA label section 6
Renal excretion considerations
ModerateFORZINITY FDA label sections 8.6 and 12.3 (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Benzyl alcohol preservative in FORZINITY formulation
ModerateFORZINITY FDA label, Description and Warnings (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Pregnancy and lactation safety unknown
ModerateFORZINITY FDA label sections 8.1 and 8.2 (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Unregulated products sold online: purity and IP concerns
HighFORZINITY FDA label (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75); structure/mechanism review PMID 39940712
Interaction summary(8)
Rated by direction with this peptide
Metformin and other MATE1 / renal cation transporter substrates (e.g. dofetilide, pindolol)
CautionModerateThe FDA label's in vitro transporter work identifies elamipretide as a MATE1 inhibitor (IC50 ~3.53 uM), which could reduce renal tubular secretion of MATE1 substrates and raise their plasma exposure - most clinically relevant for metformin, where increased levels carry lactic acidosis risk. This is an in vitro-derived caution; no clinical DDI study with metformin was reported.
FORZINITY FDA label section 12.3, Drug Interaction Studies (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Drugs requiring renal clearance, and severe renal impairment / dialysis
CautionModerateElamipretide is ~100% renally recovered within 48 hours, so severe renal impairment (eGFR <30 mL/min, not on dialysis) requires a dose reduction per the FORZINITY label and there is no dosing guidance for dialysis patients; co-administration with nephrotoxic agents that further reduce GFR would compound accumulation.
FORZINITY FDA label sections 8.6 and 12.3
Aspirin, clopidogrel, and heparin
NeutralLowDedicated drug-interaction studies found no clinically significant interaction between elamipretide and these antiplatelet/anticoagulant agents (no PK change, preserved antiplatelet/anti-thrombotic activity, no aPTT or anti-factor Xa impact), so standard cardiovascular co-medication does not require adjustment.
FORZINITY FDA label section 12.3, Drug Interaction Studies
CYP450-metabolized drugs generally
NeutralLowElamipretide does not inhibit or induce the major CYP enzymes and is cleared by sequential peptidase degradation to inactive M1/M2 fragments rather than hepatic oxidation, so broad CYP-mediated interactions are not expected.
FORZINITY FDA label section 12.3
Anthracyclines (doxorubicin) and other cardiotoxic chemotherapy
ProtectiveTheoreticalCardiolipin peroxidation is a core mechanism of anthracycline cardiotoxicity and SS-31 attenuates doxorubicin-induced cardiac mitochondrial injury in animal models, but no human trial has tested this combination and any oncology co-use should not be assumed safe or beneficial.
Mechanistic/preclinical literature summarized in PMID 35037146 and PMID 40294492; no human data
Cisplatin, aminoglycosides, and other mitochondrially nephrotoxic/ototoxic agents
ProtectiveTheoreticalRodent studies show SS-31 mitigates cisplatin-type tubular mitochondrial injury and aminoglycoside ototoxicity, consistent with its cardiolipin-stabilizing mechanism, but this is animal-only and has never been tested prospectively in humans.
Preclinical reviews PMID 35037146, PMID 40294492; aged-kidney protection PMID 28063595
NAD+ precursors (NMN, nicotinamide riboside)
SynergisticTheoreticalIn aged mouse hearts SS-31 and NMN both improved function but through largely non-overlapping proteomic and metabolic pathways, suggesting additive potential - however the combination itself was not tested and there is no human data, so 'synergy' is an inference, not a finding.
PMID 32779818 (Whitson, Aging Cell 2020)
Other benzyl-alcohol-preserved injectables (relevant in neonates, low body weight, or high cumulative dosing)
CautionModerateFORZINITY supplies 20 mg/mL benzyl alcohol and is not approved in neonates because of metabolic acidosis, neurotoxicity, and gasping syndrome risk; total benzyl alcohol load should be considered when other preserved parenteral products are used concurrently.
FORZINITY FDA label, Description and Warnings (DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75)
Known risks(7)
Injection site reactions
Low (most common adverse event)The most frequently reported side effect in all clinical trials. Includes redness, swelling, itching, or mild pain at the injection site. Reported in a majority of participants across the TAZPOWER, MMPOWER-3, and ReCLAIM-2 trials. Generally mild to moderate and self-limiting. This was the most common adverse event over the 168-week TAZPOWER open-label extension.
Hypersensitivity reactions
Moderate to High (rare but potentially serious)The FORZINITY prescribing label warns of hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention. Reported manifestations include skin rash, papular lesions, eczematous dermatitis, facial swelling, and respiratory symptoms including cough. Patients should be monitored for signs of hypersensitivity. Discontinuation is recommended if serious reactions occur.
Headache, dizziness, nausea, abdominal pain, and fatigue
Low to ModerateReported as mild to moderate in clinical trials. These adverse events were generally transient and did not lead to treatment discontinuation. The overall tolerability profile was favorable across all trials with no treatment-related serious adverse events attributed to these symptoms.
Renal excretion considerations
Moderate (in renal impairment)SS-31 is completely excreted by the kidneys — 100% of the peptide and its metabolites are detected in urine. Patients with severe renal impairment (eGFR < 30 mL/min) require a dose reduction; see the FORZINITY label. FORZINITY has not been studied in patients on dialysis. Concurrent use with nephrotoxic drugs (aminoglycosides, NSAIDs) should be monitored carefully as they may alter elamipretide clearance.
Benzyl alcohol preservative in FORZINITY formulation
High (neonates only)FORZINITY injection contains benzyl alcohol as a preservative. Serious and fatal adverse reactions including gasping syndrome have occurred in neonates (<2,500 g or gestational age <34 weeks) receiving benzyl alcohol-containing products intravenously. FORZINITY is not approved for neonates. Not relevant for adult longevity use but important for prescribers to be aware of.
Pregnancy and lactation safety unknown
Human pregnancy and lactation data unavailable; not a labeled contraindication.No adequate safety data exists for elamipretide use during pregnancy or lactation. Given its mitochondrial-targeting mechanism and potential effects on cellular bioenergetics during development, elamipretide should not be used during pregnancy or breastfeeding unless the potential benefit justifies the potential risk.
Unregulated products sold online: purity and IP concerns
ModerateUnregulated SS-31 products sold online have unvalidated purity, potency, and sterility. Patent disputes have limited supply, increasing the risk of counterfeit or low-quality products.
Drug interactions(5)
Nephrotoxic drugs (aminoglycosides, NSAIDs, cisplatin)
SS-31 is 100% renally excreted. Concurrent use with nephrotoxic drugs may impair renal clearance of elamipretide, potentially increasing plasma levels and risk of adverse effects. Patients with pre-existing renal impairment using nephrotoxic agents should have renal function monitored regularly; the FORZINITY label sets a reduced dose for severe renal impairment (eGFR < 30 mL/min).
Other mitochondrial-targeted agents (MitoQ, CoQ10, idebenone, NAD+ precursors)
SS-31 targets the inner mitochondrial membrane and modulates ETC supercomplex organization. Concurrent use with other mitochondrial-targeted agents has not been formally studied. Additive or synergistic effects on mitochondrial bioenergetics are theoretically possible but unpredictable. The combination of SS-31 with NAD+ precursors (NMN, NR) has been explored preclinically but clinical interaction data is lacking.
Antioxidants (high-dose vitamin C, vitamin E, N-acetylcysteine)
SS-31's dimethyltyrosine residue has intrinsic antioxidant activity through radical scavenging. High-dose exogenous antioxidants could theoretically interfere with or amplify the redox modulation that underlies SS-31's effects. However, SS-31's primary mechanism is cardiolipin stabilization and ETC organization rather than simple antioxidant activity, so interactions are likely modest. No formal interaction studies have been conducted.
Drugs requiring renal clearance (metformin, lithium, digoxin)
Since SS-31 is completely renally excreted, competition for renal clearance pathways is theoretically possible with other renally cleared drugs. No clinical pharmacokinetic interaction studies have been published. Monitoring renal function and drug levels is advisable when combining elamipretide with renally cleared narrow therapeutic index drugs.
Immunosuppressants (cyclosporine, tacrolimus)
Calcineurin inhibitors like cyclosporine and tacrolimus are known mitochondrial toxins. SS-31 may partially counteract their mitochondrial damage, which could be therapeutically beneficial but also alter the expected pharmacodynamic profile. Preclinical studies have shown SS-31 protects against cisplatin-induced nephrotoxicity and may similarly protect against calcineurin inhibitor nephrotoxicity, but this has not been confirmed in clinical settings.
Research & benefits
Evidence base
- Evidence Level
- Phase 2-3
- Total Studies
- 120
- Human Studies
- 12
SS-31's clinical evidence is the most extensive of any mitochondria-targeted peptide. The TAZPOWER trial in Barth syndrome (Phase 2/3 with 168-week open-label extension, 12 patients) achieved FDA accelerated approval based on >45% improvement in knee extensor muscle strength and sustained improvements in 6MWT, cardiac function, and fatigue scores. The MMPOWER-3 trial (218 PMM patients, Phase 3) failed co-primary endpoints but revealed a significant 6MWT improvement in the nDNA variant subgroup, suggesting elamipretide is effective when ETC protein subunits are structurally normal but membrane organization is disrupted. The ReCLAIM-2 trial (176 dry AMD patients, Phase 2) did not meet primary endpoints but showed 43-47% reduction in ellipsoid zone attenuation progression and improved low-light vision. The PROGRESS-HF trial (71 HFrEF patients, Phase 2) and EMBRACE-STEMI trial (STEMI patients, Phase 2a) failed primary endpoints. Roshanravan et al. 2021 (39 older adults, RCT) demonstrated improved mitochondrial ATP production after a single dose. The preclinical evidence base is exceptionally strong, with consistent reversal of age-related mitochondrial dysfunction across cardiac, skeletal muscle, renal, and retinal models in aged mice.
Researched for(6)
Rated by confidence in the evidence
Reversal of age-related mitochondrial dysfunction and improved ATP production
MediumSmall human trial showed improved muscle ATP production, backed by extensive animal data.
PMID 34264994 (Roshanravan, PLoS One 2021, randomized placebo-controlled, older adults, in vivo ATPmax); supporting animal work PMID 32779818, PMID 34480713
Reversal of age-related cardiac diastolic dysfunction
LowReversed diastolic dysfunction in aged mice across several studies, not tested in aging humans.
PMID 32648542 (Chiao, eLife 2020, mouse); PMID 32779818 (Whitson, Aging Cell 2020, mouse); PMID 36250163 (Nickel 2022, mouse); human HF context PMID 29217757 (Daubert, Circ Heart Fail 2017)
Improved skeletal muscle performance and exercise tolerance during aging
LowAnimal studies show improved muscle energetics, but a human trial missed the exercise function endpoint.
PMID 34264994 (human RCT, ATP not function); PMID 37268435 (Karaa, Neurology 2023, MMPOWER-3, 6MWT endpoint not met)
Retinal protection and preservation of visual function in dry AMD
LowThe Phase II trial missed both primary endpoints. Secondary retinal-structure measures and a categorical visual-acuity analysis favored treatment.
PMID 39605874 (Ehlers, Ophthalmology Science 2025, ReCLAIM-2); PMID 36246181 and PMID 36246187 (ReCLAIM phase 1)
Cardiolipin stabilization and mitochondrial cristae preservation
MediumWell established in lab and animal studies, indirectly supported by FDA approval for Barth syndrome.
FORZINITY (elamipretide) FDA label, DailyMed setid 146bf34c-76f2-48db-ac07-fb29cce2cd75; review PMID 39940712; PMID 35037146
Renal protection and improved kidney function in aging
LowImproved kidney structure in aged mice, no human studies on age-related kidney decline.
PMID 28063595 (Sweetwyne, Kidney Int 2017, aged mice)
Benefits(6)
Reversal of age-related mitochondrial dysfunction and improved ATP production
Siegel et al. 2013 (Aging Cell, PMID 23692570) — A single SS-31 treatment restored in vivo mitochondrial energetics (ATPmax, P/O coupling, PCr/ATP) to young levels in aged mouse skeletal muscle within 1 hour, with 8 days of treatment increasing whole-animal endurance capacity. SS-31 had no observable effect on young muscle. Roshanravan et al. 2021 (PLOS ONE, PMID 34264994) — Randomized, double-blind, placebo-controlled trial in 39 healthy older adults (ages 60-85) showed a single 2-hour infusion of elamipretide improved in vivo mitochondrial ATP production (ATPmax) in skeletal muscle measured by phosphorus MRS. Pharaoh et al. 2023 (GeroScience, PMID 37462785) — Elamipretide improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT), rescuing muscle force and heart systolic function.
Reversal of age-related cardiac diastolic dysfunction
Chiao et al. 2020 (eLife, PMID 32648542) — 8-week treatment of old mice (24 months) with SS-31 substantially reversed pre-existing diastolic dysfunction, normalized proton leak, and reduced mitochondrial ROS in cardiomyocytes from old mice. This was accompanied by reduced protein oxidation and a more reduced protein thiol redox state in old hearts. Dai et al. 2014 (J Am Heart Assoc) — SS-31 improved cardiac function in models of pressure overload-induced heart failure. Elamipretide Improves Mitochondrial Function in the Failing Human Heart (Brown et al. 2019, JACC Basic Transl Sci) — demonstrated benefits in human cardiac tissue.
Improved skeletal muscle performance and exercise tolerance during aging
Campbell et al. 2019 (Free Radical Biology and Medicine, PMC6588449) — 8 weeks of SS-31 in aged mice restored redox homeostasis, improved mitochondrial quality, and increased exercise tolerance without increasing mitochondrial content, but by restoring function of existing mitochondria. Nickel et al. 2022 (Aging Pathobiology and Therapeutics) — 10-month elamipretide treatment in 18-month-old mice enhanced healthy aging phenotypes, mitigated frailty accumulation, and partially reversed declines in cardiac strain and muscle fatigue resistance in both sexes, though without detectable changes in DNA methylation or transcriptomic age.
Retinal protection and preservation of visual function in dry AMD
ReCLAIM-2 Phase 2 trial (Ophthalmology Science, 2024) — In 176 patients with geographic atrophy from dry age-related macular degeneration, elamipretide 40 mg SC daily for 12 months resulted in 43% less progression of total ellipsoid zone (EZ) attenuation and 47% less partial EZ attenuation vs placebo. The primary visual-acuity and geographic-atrophy endpoints were not met. A secondary analysis found more patients gained at least 10 low-luminance visual-acuity letters. FDA confirmed ellipsoid zone attenuation as an approvable endpoint following end-of-Phase 2 meeting.
Cardiolipin stabilization and mitochondrial cristae preservation
Szeto 2014 (British Journal of Pharmacology, vol 171(8):2029-2050) — Comprehensive review establishing SS-31 as the first-in-class cardiolipin-protective compound that restores mitochondrial bioenergetics by modulating the hydrophobic interaction between cytochrome c and cardiolipin, promoting electron carrying function. Chavez et al. 2020 (PNAS, PMID 32554501) — Chemical cross-linking/mass spectrometry identified SS-31 interactors as functional components in ATP production, including direct binding to ANT and ATP synthase of the ATP synthasome supercomplex. Mitchell et al. 2020 (J Biol Chem, PMID 32273339) — SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action.
Renal protection and improved kidney function in aging
Zhang et al. 2022 (PMC9192202) — Comprehensive review showing SS-31 ameliorates kidney disease through mitochondrial protection: subcutaneous SS-31 for 8 weeks improved kidney glomerular architecture in old mice alongside improvements in redox homeostasis and skeletal muscle function. SS-31 protected against ischemia-reperfusion kidney injury, diabetic nephropathy, and age-related glomerulosclerosis in preclinical models.
Key studies(10)
Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice
Preclinical original researchYoung (5 mo) and old (27 mo) C57BL/6 miceSingle treatment (1 hour) and 8-day treatmentSiegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ
Aging Cell
2013
A single SS-31 treatment restored in vivo mitochondrial energetics to young levels in aged mouse skeletal muscle within 1 hour: age-related declines in resting and maximal mitochondrial ATP production (ATPmax), coupling of oxidative phosphorylation (P/O), and cell energy state (PCr/ATP) were rapidly reversed. SS-31 had no observable effect on young muscle. 8 days of treatment increased whole-animal endurance capacity. Effects were associated with more reduced glutathione redox status and lower mitochondrial H2O2 emission.
Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice
Preclinical original researchYoung (5 mo) and old (26 mo) C57BL/6 mice8 weeks subcutaneous SS-31Campbell MD, Duan J, Samber AT, Walber MJ, Muehlbauer MJ, Bain JR, Newgard CB, Szeto HH, Rabinovitch PS, Marcinek DJ
Free Radical Biology and Medicine
2019
8 weeks of SS-31 treatment restored redox homeostasis, improved mitochondrial quality, and increased exercise tolerance in aged mice without increasing mitochondrial content. Also improved kidney glomerular architecture in old mice. Demonstrates that restoring the function of existing mitochondria (rather than biogenesis) is sufficient to reverse age-related functional decline.
Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice
Preclinical original researchOld (24 mo) and young (4-6 mo) C57BL/6 mice8 weeks SS-31 treatmentChiao YA, Zhang H, Sweetwyne M, Whitson J, Ez YS, Campbell MD, Marcinek DJ, Rabinovitch PS
eLife
2020
8 weeks of SS-31 treatment substantially reversed pre-existing diastolic cardiac dysfunction in old mice. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift toward a more reduced protein thiol redox state in old hearts. Demonstrates that age-related cardiac dysfunction driven by mitochondrial dysfunction is reversible even when initiated in late life.
Mitochondrial protein interaction landscape of SS-31
Molecular pharmacology / proteomicsIn vitro and in vivo cross-linking mass spectrometryN/A (mechanistic study)Chavez JD, Tang X, Campbell MD, Reyes G, Kramer PA, Stuppard R, Keller A, Zhang H, Rabinovitch PS, Marcinek DJ, Bruce JE
Proceedings of the National Academy of Sciences (PNAS)
2020
Used chemical cross-linking/mass spectrometry to provide the first direct evidence for specific interactions between SS-31 and mitochondrial proteins. Identified SS-31 interactors as functional components in ATP production and 2-oxoglutarate metabolism. SS-31 binds directly to ANT and ATP synthase (members of the ATP synthasome supercomplex). Treatment improves ADP sensitivity, increases ATP production, and improves physiological function in old muscles.
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
Phase 2/3 RCT with open-label extension12 patients (10 entered OLE, 8 completed 168 weeks)28-week RCT + 168-week open-label extensionThompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ
Genetics in Medicine
2024
Elamipretide 40 mg SC daily was well tolerated over 168 weeks with injection-site reactions as the most common adverse event. Sustained long-term improvements in functional assessments and cardiac function in Barth syndrome patients. At 36 weeks in the open-label extension, significant improvements in 6MWT (+95.9 m) and BTHS-SA (-2.1 points). Knee extensor muscle strength improved by >45%. This data formed the basis for FDA accelerated approval of FORZINITY in September 2025.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Phase 3 randomized controlled trial218 adults with genetically confirmed PMM24 weeks, elamipretide 40 mg SC daily vs placeboKaraa A, Haas R, Goldstein A, Vockley J, Douglas Weaver W, Cohen BH
Neurology
2023
Failed to meet co-primary endpoints: no statistically significant difference between elamipretide and placebo in 6MWT distance or PMMSA total fatigue score over 24 weeks in the overall population. However, the prespecified subgroup with nuclear DNA (nDNA) pathogenic variants experienced significant 6MWT improvement, while patients with mitochondrial DNA (mtDNA) variants showed no difference vs placebo — suggesting elamipretide is effective when ETC protein subunits are structurally normal but membrane organization is disrupted.
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
Randomized, double-blind, placebo-controlled trial39 healthy older adults (ages 60-85, 46% female)Single 2-hour intravenous infusionRoshanravan B, Liu SZ, Ali AS, Shankland EG, Goss C, Amory JK, Robertson HT, Marcinek DJ, Conley KE
PLOS ONE
2021
First human aging trial of elamipretide. A single 2-hour infusion improved in vivo mitochondrial ATP production (ATPmax) in older adult skeletal muscle measured by phosphorus magnetic resonance spectroscopy (31P MRS). Participants were enrolled based on the presence of poorly functioning mitochondria. Demonstrates translatability of preclinical aging results to human physiology.
Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice
Preclinical long-term treatment studyC57BL/6 mice starting at 18 months of age10 months (3 mg/kg SC, 5 days/week)Nickel K, Zhu L, Mangalindan R, Snyder JM, Tucker M, Whitson J, Sweetwyne M, Valencia AP, Klug J, Jiang Z, Marcinek DJ, Rabinovitch P, Ladiges W
Aging Pathobiology and Therapeutics
2022
Long-term elamipretide treatment enhanced healthy aging phenotypes in both male and female mice on regular chow or high-fat diet. Reversed preexisting loss of function in multiple organ systems including skeletal muscle, heart, and brain. Females showed better cognitive performance and maintenance of body composition; males showed preserved rotating rod performance. Elamipretide significantly blunted increases in frailty during aging.
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
Phase 2 randomized, double-blind, placebo-controlled trial71 patients with HFrEF (LVEF <= 40%)28 days, placebo vs 4 mg vs 40 mg SC dailyButler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Shah SJ, Voors AA, Zamani P, Zile MR, Berman D, Brinker JA, Burkhoff D, Filip C, Jaber WA, Packer M, Piña IL, Spertus JA, Whellan DJ, DiMaria JM, Handberg EM, Gibson CM
Journal of Cardiac Failure
2020
Elamipretide was well tolerated but did not improve left ventricular end-systolic volume (LVESV) at 4 weeks in patients with stable HFrEF compared with placebo. Secondary analyses of ejection fraction and LV end-diastolic volume also showed no significant differences. The short treatment duration (28 days) and stable HF population may have limited ability to detect treatment effects that require longer exposure for cardiac remodeling.
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation
Phase 2 randomized, double-blind, placebo-controlled trial176 patients with geographic atrophy from dry AMD12 months, elamipretide 40 mg SC daily vs placeboStealth BioTherapeutics investigators
Ophthalmology Science
2024
Did not meet primary endpoints (mean change in low-luminance BCVA and GA progression), but demonstrated significant biologic activity: 43% less progression of total ellipsoid zone (EZ) attenuation and 47% less partial EZ attenuation vs placebo. A secondary categorical visual-acuity analysis favored treatment. Correlations between EZ preservation and visual function support potential for disease modification. FDA confirmed EZ attenuation as an approvable endpoint.
What research suggests over time
Weeks 2-4
Phase 2 trial dataSubjective fatigue improvements reported in mitochondrial myopathy studies; objective lab markers shift slowly.
Months 2-3
TAZPOWER Phase 2/3Improved exercise capacity in primary mitochondrial myopathy and Barth syndrome cohorts.
Long-term
Phase 2/3 + extension>45% improvement in knee extensor strength sustained at 168-week open-label extension in Barth syndrome (FORZINITY accelerated approval Sept 2025).
Prescribing labels
FDA-Approved Labels
This page does not list doses. Each product below has an FDA label with its prescribing information.
- Protocol
- Forzinity (elamipretide)
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
Monitoring & labs
Baseline before starting, then per marker schedule during protocol.
Baseline labs(5)
Complete Blood Count (CBC)
Optimal All markers within mid-rangeEstablishes baseline for detecting hematological changes.
Lab normal Standard reference ranges
Comprehensive Metabolic Panel (CMP)
Optimal Liver enzymes <25, glucose 75–90, eGFR >90Liver and kidney function baseline.
Lab normal Standard reference ranges
C-Reactive Protein (CRP)
Optimal Under 1.0 mg/LChronic inflammation is a key aging biomarker.
Lab normal Under 3.0 mg/L
IGF-1
Optimal 150–250 ng/mL (adults)Growth factor associated with aging pathways.
Lab normal Age-dependent (~80–280 ng/mL)
Fasting insulin
Optimal 2–6 μIU/mLInsulin sensitivity is a core longevity metric.
Lab normal 2.6–24.9 μIU/mL
Ongoing tracking(3)
CRP
Every 6-8 weeksOptimal Under 1.0 mg/LTrack chronic inflammation changes.
Lab normal Under 3.0 mg/L
Fasting insulin + glucose
Every 8-12 weeksOptimal 2–6 μIU/mLMonitor metabolic health markers.
Lab normal 2.6–24.9 μIU/mL
Liver enzymes (ALT/AST)
Every 8 weeksOptimal ALT & AST under 25 U/LHepatic monitoring.
Lab normal ALT 7–56, AST 10–40 U/L
Retest schedule(5)
Baseline
critical
Before starting
Full baseline panel — establish reference values for all monitored markers.
Early follow-up
critical
Week 4-6
Spot-check for early changes — focus on glucose, liver enzymes, and any peptide-specific markers.
Mid-protocol
critical
Week 12
Comprehensive retest. Compare all markers to baseline.
Ongoing
standard
Quarterly
Continued monitoring during extended protocols.
Post-protocol
standard
4-6 weeks after stopping
Confirm return to baseline. Important for GH and metabolic peptides.
When to stop and reassess(3)
ALT or AST
stopAbove 2× upper limit of normal (>~80 U/L)
Stop protocol and consult a provider — possible drug-induced liver injury.
eGFR
stopDrop of >15 mL/min/1.73m² from baseline, or below 60
Stop protocol and consult a provider — possible kidney function decline.
Symptoms
stopNew severe symptoms correlating with lab changes
Stop protocol and seek medical evaluation immediately.
Lab monitoring helps track your body's response to SS-31 (Elamipretide). Any unexplained changes should prompt discussion with your prescribing provider.
Regulation & availability
Why researchers look at it
In aged mice, a single treatment restored mitochondrial energy output to young levels within one hour, and a 39-person randomized human trial confirmed improved ATP production in older adults after a single dose. FDA-approved for Barth syndrome in September 2025, validating the cardiolipin-targeting mechanism in humans. The Phase 3 myopathy trial and Phase 2 heart failure trial missed primary endpoints, but the mechanistic foundation remains compelling for future aging-focused research.
- Estimated cost
- About $59,600 per 28-day supply at the US cash price (Forzinity, Drugs.com price guide, checked 2 Nov 2026); specialty pharmacy only
- FDA status
- FDA ACCELERATED APPROVAL (September 19, 2025) for FORZINITY (elamipretide HCl injection). Approved to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This was the first and only FDA-approved treatment for Barth syndrome and the first approved mitochondria-targeted peptide therapeutic. Regulatory pathway: The accelerated approval was based on improved knee extensor muscle strength (>45% improvement), an intermediate clinical endpoint reasonably likely to predict clinical benefit, from the TAZPOWER Phase 2/3 trial and its 168-week open-label extension. FDA requires Stealth BioTherapeutics to conduct a randomized, double-blind, placebo-controlled confirmatory trial to verify clinical benefit. The approval followed an extended regulatory dialogue, including an NDA filing in August 2021, a Refusal to File letter in October 2021, NDA resubmission in 2025, a Complete Response Letter in May 2025, and final accelerated approval in September 2025. Special designations: Orphan Drug Designation (Barth syndrome), Fast Track Designation (primary mitochondrial myopathy, January 2016; Leber's Hereditary Optic Neuropathy, December 2017), Rare Pediatric Disease Designation (Barth syndrome, March 2020), and EMA Orphan Drug Designation (Barth syndrome). Elamipretide is NOT approved for age-related mitochondrial dysfunction, heart failure, age-related macular degeneration, general aging, or any longevity indication. Those uses would constitute off-label prescribing.
- WADA status
- Elamipretide is not named on the 2026 WADA Prohibited List. Its FDA approval means S0 does not apply solely because it is used off-label or without a prescription. Athletes should obtain a compound-specific determination from their anti-doping organization.
- Prescribability
- SS-31 (elamipretide) received FDA accelerated approval on September 19, 2025, under the brand name FORZINITY, specifically to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms (66 lbs). This makes it the first and only FDA-approved treatment for Barth syndrome. FORZINITY is a prescription medication given by subcutaneous injection; dosing, including the adjustment for severe renal impairment, follows the FDA label. For indications beyond Barth syndrome — including age-related mitochondrial dysfunction, longevity, cardiac aging, or skeletal muscle decline — elamipretide is NOT FDA-approved and would constitute off-label use. Physicians may legally prescribe FDA-approved drugs off-label based on clinical judgment, but insurance coverage for off-label FORZINITY is unlikely and the cost of the branded product is expected to be very high given its orphan drug status. Compounding of elamipretide is limited by FDA's bulk-substance rules and the restriction on compounding copies of an approved drug (Forzinity is approved). Some clinics advertise compounded elamipretide; that does not make it an eligible or approved product. Legitimate access for anti-aging purposes remains limited. A valid prescription from a licensed healthcare provider is required for any clinical use of FORZINITY.
- Availability
- SS-31 (elamipretide) availability is stratified by indication and geography. FDA-approved product: FORZINITY has been available by prescription in the United States since September 2025 for the treatment of Barth syndrome. FORZINITY is manufactured by Stealth BioTherapeutics as a subcutaneous injection formulation. As an orphan drug for an ultra-rare disease (~200 diagnosed patients in the US), it is expected to be very expensive. Off-label prescription by physicians is legally permitted, but insurance coverage for non-Barth uses is unlikely. Clinical trials: elamipretide continues in Phase 3 trials for dry age-related macular degeneration (ReNEW trial) and primary mitochondrial myopathy, providing clinical access for enrolled participants; ClinicalTrials.gov lists multiple active and recruiting studies. Compounding: unlike many longevity peptides, SS-31 is NOT on the FDA's Category 1 or Category 2 bulk drug substances lists for compounding, and active patent protections limit compounding pharmacy preparation. International: not approved in any other country as of early 2026. EMA has granted Orphan Drug Designation for Barth syndrome.
International status
EU
EU orphan drug designation for Barth syndrome, granted May 20, 2021; marketing authorization not established.
US
FDA-approved (Forzinity) for Barth syndrome
Japan
Orphan drug designation
Regulatory timeline(20)
- Early 2000sSS-31 discovered by Dr. Hazel Szeto (Weill Cornell Medical College) and Dr. Peter Schiller (Clinical Research Institute of Montreal) during opioid receptor studies. The Szeto-Schiller (SS) peptide family identified as selectively targeting mitochondria via an alternating aromatic-cationic motif.
- 2004-2008Foundational preclinical research published demonstrating SS-31's mitochondrial targeting, cardiolipin binding, antioxidant properties, and protective effects in ischemia-reperfusion injury, neurodegeneration, and cardiac models.
- 2010SS-31 enters clinical development with Stealth BioTherapeutics (formerly Stealth Peptides Inc., Newton, MA) under clinical formulation names Bendavia (MTP-131) and Elamipretide. Phase 1 trials establish safety in healthy volunteers.
- 2013Siegel et al. publish landmark aging study in Aging Cell showing SS-31 rapidly restores mitochondrial energetics to young levels in aged mice (PMID 23692570). EMBRACE-STEMI Phase 2a trial initiated for acute MI.
- 2014Szeto publishes comprehensive review in British Journal of Pharmacology establishing SS-31 as 'first-in-class cardiolipin-protective compound.' EMBRACE-STEMI results show no reduction in infarct size.
- 2016-01FDA grants Fast Track designation for elamipretide in primary mitochondrial myopathy. Generic name 'elamipretide' adopted in alignment with WHO/USAN standards, replacing MTP-131 and Bendavia.
- 2017-01TAZPOWER Phase 2/3 trial initiated for Barth syndrome (NCT03098797). MMPOWER-3 Phase 3 trial initiated for primary mitochondrial myopathy (NCT03323749).
- 2018-03-22FDA grants Orphan Drug designation for elamipretide in Barth syndrome.
- 2017-12FDA grants Fast Track designation for elamipretide in Leber's Hereditary Optic Neuropathy.
- 2019Campbell et al. publish 8-week SS-31 treatment study reversing age-related redox stress and improving exercise tolerance in aged mice (PMC6588449).
- 2020-03FDA grants Rare Pediatric Disease designation for elamipretide in Barth syndrome.
- 2020-07Chiao et al. publish eLife study demonstrating SS-31 reverses cardiac diastolic dysfunction in old mice (PMID 32648542). Chavez et al. publish PNAS study mapping SS-31 mitochondrial protein interactions (PMID 32554501). Butler et al. publish PROGRESS-HF results showing no improvement in LVESV in HFrEF (PMID 32068002).
- 2021-07Roshanravan et al. publish first human aging trial showing single-dose elamipretide improves ATPmax in older adults (PMID 34264994).
- 2021-08Stealth BioTherapeutics files NDA for elamipretide in Barth syndrome.
- 2021-10FDA issues Refusal to File letter for elamipretide NDA.
- 2023MMPOWER-3 Phase 3 trial results published (Neurology, PMID 37268435): failed co-primary endpoints overall but significant improvement in nDNA variant subgroup.
- 2024TAZPOWER 168-week OLE results published (Genetics in Medicine, PMID 38602181) showing sustained long-term efficacy and tolerability. ReCLAIM-2 Phase 2 results published showing significant ellipsoid zone preservation in dry AMD.
- 2025-05FDA issues Complete Response Letter for elamipretide NDA resubmission. Stealth BioTherapeutics resolves remaining regulatory milestones.
- 2025-09-19FDA grants accelerated approval to FORZINITY (elamipretide HCl injection) for Barth syndrome — the first FDA-approved mitochondria-targeted peptide therapeutic and first treatment for Barth syndrome.
- 2025-2026Phase 3 ReNEW trial ongoing for elamipretide in dry age-related macular degeneration. Stealth BioTherapeutics also developing second-generation candidate bevemipretide (SBT-272) for ophthalmic and neurological diseases.
Sources & FAQs
Research sources(20)
- Siegel et al. 2013 — SS-31 rapidly restores mitochondrial energetics in aged muscle (Aging Cell)
- Campbell et al. 2019 — SS-31 reverses age-related redox stress and improves exercise tolerance (Free Radical Biology and Medicine)
- Chiao et al. 2020 — Late-life SS-31 reverses cardiac dysfunction in old mice (eLife)
- Chavez et al. 2020 — Mitochondrial protein interaction landscape of SS-31 (PNAS)
- Mitchell et al. 2020 — SS-31 binds lipid bilayers and modulates surface electrostatics (J Biol Chem)
- Roshanravan et al. 2021 — Single-dose elamipretide improves ATPmax in older adults (PLOS ONE)
- Nickel et al. 2022 — Long-term elamipretide enhances healthy aging phenotypes in mice
- Pharaoh et al. 2023 — Elamipretide improves ADP sensitivity via ANT in aged mitochondria (GeroScience)
- Thompson et al. 2024 — TAZPOWER 168-week OLE results in Barth syndrome (Genetics in Medicine)
- Karaa et al. 2023 — MMPOWER-3 Phase 3 trial in PMM (Neurology)
- Butler et al. 2020 — PROGRESS-HF Phase 2 trial in HFrEF (Journal of Cardiac Failure)
- ReCLAIM-2 Phase 2 trial — Elamipretide in dry AMD (Ophthalmology Science, 2024)
- ReCLAIM Phase 1 — Elamipretide in dry AMD and NCGA
- Szeto 2014 — First-in-class cardiolipin-protective compound review (Br J Pharmacol)
- Zhang et al. 2022 — SS-31 ameliorates kidney disease (PMC review)
- Kamel et al. 2025 — Elamipretide review: structure, mechanism, therapeutic potential (MDPI)
- Stealth BioTherapeutics — FORZINITY FDA approval press release
- FORZINITY prescribing information (FDA label)
- Elamipretide — Wikipedia
- WADA 2025/2026 Prohibited List
Frequently asked questions(5)
How does SS-31 target mitochondria specifically?
SS-31 has an alternating aromatic-cationic motif (D-Arg-Dmt-Lys-Phe-NH2) with two positively charged amino acids that facilitate electrostatic attraction to the negatively charged inner mitochondrial membrane, which is rich in cardiolipin. Unlike other mitochondrial-targeting strategies that rely on mitochondrial membrane potential (which is often compromised in dysfunctional mitochondria), SS-31 uptake is energy-independent and non-saturable, allowing it to reach dysfunctional mitochondria effectively. It concentrates 1000-5000 fold in mitochondria relative to the cytoplasm.
Can SS-31 be used for general anti-aging purposes?
Preclinical evidence is very promising: SS-31 has reversed age-related declines in cardiac function, skeletal muscle performance, exercise tolerance, and mitochondrial energetics in aged mice, and a single dose improved mitochondrial ATP production in older human adults. However, SS-31 is only FDA-approved for Barth syndrome, and access for anti-aging purposes is limited by patent protections, high cost (orphan drug pricing), and the absence of clinical trials specifically targeting aging endpoints in humans. Off-label prescribing is theoretically possible through FORZINITY but practically difficult due to cost.
Why did SS-31 fail in heart failure and mitochondrial myopathy trials?
The PROGRESS-HF trial used only 28 days of treatment in stable HFrEF — likely too short for cardiac remodeling, which requires months. The EMBRACE-STEMI trial used a single IV dose during acute MI — a narrow window that may not capture the prolonged ischemia-reperfusion process. The MMPOWER-3 trial failed overall but succeeded in the nDNA variant subgroup, suggesting SS-31 works when electron transport chain proteins are structurally normal but poorly organized in the membrane. Patients with primary mtDNA mutations produce structurally defective ETC proteins that cannot be rescued by membrane stabilization alone. These results have actually refined understanding of SS-31's mechanism and appropriate patient selection.
Does SS-31 affect healthy mitochondria?
No. Multiple studies have shown that SS-31 has no observable effect on normally functioning mitochondria. In Siegel et al. 2013, SS-31 restored mitochondrial energetics in aged mouse muscle but had no effect on young muscle. This selectivity for dysfunctional mitochondria is considered a safety advantage, as it avoids disrupting normal bioenergetics in healthy cells. The peptide does not accumulate in the mitochondrial matrix even at very high concentrations and does not affect mitochondrial membrane potential in healthy mitochondria.
What is the difference between SS-31 and other mitochondrial supplements like CoQ10 or MitoQ?
SS-31 is mechanistically distinct from other mitochondrial interventions. CoQ10 (ubiquinone) is a natural electron carrier in the ETC that acts as an antioxidant but has poor bioavailability and limited mitochondrial targeting. MitoQ is a TPP+-conjugated form of CoQ10 that uses membrane potential for mitochondrial targeting, but this approach is less effective when membrane potential is compromised (as in aging/disease). SS-31 targets cardiolipin specifically, stabilizing the structural organization of ETC supercomplexes rather than simply scavenging ROS. Its uptake is independent of membrane potential, making it effective in dysfunctional mitochondria where other agents cannot reach. SS-31 also directly interacts with ANT and ATP synthase to improve ADP sensitivity and ATP production.